USP1 inhibitor is cytotic in T-ALL cells by inhibiting glycolysis. (A) T-ALL cell lines (Jurkat and MOLT4) were treated with increasing concentrations of ML323 for 48 hours, followed by assessment of cell viability using a CCK-8 assay. Two-tailed t test. Data are shown as mean ± SD, n = 3. (B) Primary T-ALL cells were isolated and treated with different concentrations of ML323 for 48 hours, and the cell viability was monitored via CCK-8 assay. Two-tailed t test. Data are shown as mean ± SD, n = 3. (C) Mouse survival is shown (n = 5 in the vehicle and USP1 inhibitor ML323 [5 mg/kg] treatment cohort respectively). (D) T-ALL cell lines (Jurkat and MOLT4) were treated with 2-DG for 48 hours, followed by assessment of cell viability using a CCK-8 assay. Two-tailed t test. Data are shown as mean ± SD, n = 3. (E) Jurkat cells were treated with ML323 for 48 hours, and lactate production was analyzed. Two-tailed t test. Data are shown as mean ± SD, n = 3. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001.